Overview

Comparison of Two NN1250 Formulations in Subjects With Type 1 Diabetes

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of the trial is to investigate the pharmacodynamic properties (effect) by comparing two NN1250 (insulin degludec, IDeg) formulations in subjects with type 1 diabetes.
Phase:
Phase 1
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Insulin
Insulin, Globin Zinc
Insulin, Long-Acting